Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03752307 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses
A Phase 1 study, sponsored by University of New Mexico.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03752307 is a Phase 1 study that has completed, run by University of New Mexico. The registered enrollment target is 2 participants.
The verdict
NCT03752307, a Phase 1 study, has completed, sponsored by University of New Mexico.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a proof of concept, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of Isoxsuprine in MS subjects experiencing a typical relapse. Evidence from preclinical stroke models and experimental allergic encephalomyelitis suggest that isoxsuprine hydrochloride may have neuroprotective activity and reduce disability in animal models. Given its potential neuroprotective effects in CNS injury models, the investigators propose to test it as a safe, tolerable add on treatment for acute relapses in patients with relapsing forms of MS.
Interventions
- DRUG Placebo
- DRUG Corticosteroid
- DRUG Isoxsuprine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-02-15 |
| Est. Completion | 2023-07-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03752307
The ClinicalTrials.gov registry entry for NCT03752307 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of New Mexico, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03752307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03752307 about?
NCT03752307 is a clinical study titled "Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses". This is a proof of concept, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of Isoxsuprine in MS subjects experiencing a typical relapse. Evidence from preclinical stroke models and experimental allergic encephalomyelitis suggest that isoxsuprine hydrochloride may have neu...
What is the current status of trial NCT03752307?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2019-02-15. Estimated completion is 2023-07-06.
What interventions are being tested in trial NCT03752307?
The interventions under investigation include: Placebo (DRUG), Corticosteroid (DRUG), Isoxsuprine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03752307?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.